Compare LXFR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | ASMB |
|---|---|---|
| Founded | 1898 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.6M | 512.1M |
| IPO Year | 2002 | 2010 |
| Metric | LXFR | ASMB |
|---|---|---|
| Price | $17.27 | $20.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $52.00 |
| AVG Volume (30 Days) | ★ 337.9K | 204.2K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $384,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $55.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $19.30 |
| 52 Week High | $19.45 | $39.71 |
| Indicator | LXFR | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 36.54 |
| Support Level | $17.19 | N/A |
| Resistance Level | $17.38 | $21.93 |
| Average True Range (ATR) | 0.04 | 1.05 |
| MACD | -0.00 | 0.20 |
| Stochastic Oscillator | 58.33 | 26.27 |
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.